ALX ONCOLOGY HOLDINGS INC (ALXO)
$2.00-$0.05 (-2.44%) Today
Corey S. GoodmanALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 3 | 4,207 | $8K |
36 Form 4 filings on record, the earliest from Nov 19, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jason Lettmann - Officer | Open-market sale | Common Stock | 2,230 | $1.93 | $4K | |
| Shelly Pinto - Officer | Open-market sale | Common Stock | 573 | $1.93 | $1K | |
| Shelly Pinto - Officer | Open-market sale | Common Stock | 1,404 | $2.04 | $3K | |
| Jeff E. Knight - Officer | Grant or award | Stock option (right to buy) | 800,000 | $0.00 | - | |
| Barbara Klencke - Officer | Grant or award | Stock option (right to buy) | 100,000 | $0.00 | - | |
| Jason Lettmann - Officer | Open-market sale | Common Stock | 12,311 | $2.17 | $27K | |
| Shelly Pinto - Officer | Open-market sale | Common Stock | 903 | $2.17 | $2K | |
| Barbara Klencke - Officer | Grant or award | Stock option (right to buy) | 700,000 | $0.00 | - | |
| Shelly Pinto - Officer | Open-market sale | Common Stock | 565 | $2.27 | $1K | |
| Jason Lettmann - Officer | Tax withholding / forfeiture | Common Stock | 2,201 | $2.27 | $5K | |
| Corey S. Goodman | Open-market purchase | Common Stock | 3,184,713 | $1.57 | $5.00M | |
| Harish Shantharam - Officer | Grant or award | Stock option (right to buy) | 303,000 | $0.00 | - | |
| Shelly Pinto - Officer | Grant or award | Stock option (right to buy) | 192,000 | $0.00 | - | |
| Jason Lettmann - Officer | Grant or award | Stock option (right to buy) | 912,000 | $0.00 | - | |
| Corey S. Goodman | Grant or award | Stock Option (right to buy) | 40,400 | $0.00 | - | |
| J. Scott Garland | Grant or award | Stock option (right to buy) | 40,400 | $0.00 | - | |
| Alan B. Sandler | Grant or award | Stock option (right to buy) | 10,100 | $0.00 | - | |
 Daniel J. Curran | Grant or award | Stock Option (right to buy) | 16,833 | $0.00 | - | |
| Chris H. Takimoto | Grant or award | Stock option (right to buy) | 40,400 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Stock option (right to buy) | 40,400 | $0.00 | - | |
| Shelly Pinto - Officer | Open-market sale | Common Stock | 3,925 | $1.11 | $4K | |
| Shelly Pinto - Officer | Grant or award | Employee Stock Option (right to buy) | 140,000 | $0.00 | - | |
| Jason Lettmann - Officer | Grant or award | Employee Stock Option (right to buy) | 597,500 | $0.00 | - | |
| Harish Shantharam - Officer | Grant or award | Employee Stock Option (right to buy) | 198,750 | $0.00 | - | |
| Jason Lettmann - Officer | Open-market purchase | Common Stock | 21,070 | $1.07 | $22K | |
| Jason Lettmann - Officer | Open-market purchase | Common Stock | 71,163 | $1.08 | $77K | |
| Barbara Klencke | Grant or award | Stock option (right to buy) | 300,000 | $0.00 | - | |
| Harish Shantharam - Officer | Open-market purchase | Common Stock | 75,000 | $0.78 | $58K | |
| Jason Lettmann - Officer | Open-market sale | Common Stock | 2,382 | $0.64 | $2K | |
| Shelly Pinto - Officer | Open-market sale | Common Stock | 611 | $0.64 | $391 | |
| Daniel J. Curran | Grant or award | Stock option (right to buy) | 40,400 | $0.00 | - |
ALX ONCOLOGY HOLDINGS INC (ALXO) had 3 insider filings in the last 90 days, with the most recent on 2026-08-18. The full record for ALXO runs to 36 Form 4 filings, the earliest from 2024-11-19. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of ALXO were filed in the last 90 days. 5 purchases are on record for this company.
3 insider sales of ALXO were filed in the last 90 days, totaling $8K.
This page tracks ALXO Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add ALXO to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
